I
Ira Gantz
Researcher at Merck & Co.
Publications - 50
Citations - 2723
Ira Gantz is an academic researcher from Merck & Co.. The author has contributed to research in topics: Placebo & Population. The author has an hindex of 19, co-authored 50 publications receiving 1624 citations. Previous affiliations of Ira Gantz include Harvard University.
Papers
More filters
Journal ArticleDOI
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon,Richard Pratley,Samuel Dagogo-Jack,James P. Mancuso,Susan Huyck,Urszula Masiukiewicz,Bernard Charbonnel,Robert Frederich,Silvina Gallo,Francesco Cosentino,Weichung Shih,Ira Gantz,Steven G. Terra,David Z.I. Cherney,Darren K. McGuire +14 more
TL;DR: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events.
Journal ArticleDOI
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K. McGuire,Weichung Shih,Weichung Shih,Francesco Cosentino,Bernard Charbonnel,David Z.I. Cherney,Samuel Dagogo-Jack,Richard E. Pratley,Michelle Greenberg,Shuai Wang,Susan Huyck,Ira Gantz,Steven G. Terra,Urszula Masiukiewicz,Christopher P. Cannon +14 more
TL;DR: This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.
Journal ArticleDOI
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Carol Addy,Hamish Wright,Koen Van Laere,Ira Gantz,Ngozi Erondu,Bret J. Musser,Kaifeng Lu,Jinyu Yuan,Sandra M. Sanabria-Bohórquez,Aubrey Stoch,Cathy Stevens,Tung M. Fong,Inge De Lepeleire,Caroline Cilissen,Josee Cote,Kim Rosko,I.N. Gendrano,Allison Martin Nguyen,Barry Gumbiner,Paul Rothenberg,Jan de Hoon,Guy Bormans,Marleen Depré,Wai-Si Eng,Eric Ravussin,Samuel Klein,John E. Blundell,Gary A. Herman,H. Donald Burns,Richard Hargreaves,John A. Wagner,Keith Gottesdiener,John M. Amatruda,Steven B. Heymsfield +33 more
TL;DR: Mechanism-of-action studies suggest that engagement of the CB1R by taranabant leads to weight loss by reducing food intake and increasing energy expenditure and fat oxidation.
Journal ArticleDOI
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Ngozi Erondu,Ira Gantz,Bret J. Musser,Shailaja Suryawanshi,Madhuja Mallick,Carol Addy,Josee Cote,George A. Bray,Ken Fujioka,Harold Bays,Priscilla Hollander,Sandra M. Sanabria-Bohórquez,Wai-Si Eng,Bengt Långström,Richard Hargreaves,H. Donald Burns,Akio Kanatani,Takehiro Fukami,Douglas J. MacNeil,Keith Gottesdiener,John M. Amatruda,Keith D. Kaufman,Steven B. Heymsfield +22 more
TL;DR: It is suggested that solely targeting the NPY5R in future drug development programs is unlikely to produce therapeutic efficacy and the first clinical insight into the human NPY-energy homeostatic pathway is provided.
Journal ArticleDOI
Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults
Ira Gantz,Ngozi Erondu,Madhuja Mallick,Bret J. Musser,Rajesh Krishna,Wesley Tanaka,Karen Snyder,Cathy Stevens,Mark Stroh,Haiyuan Zhu,John A. Wagner,Douglas J. MacNeil,Steven B. Heymsfield,John M. Amatruda +13 more
TL;DR: Intranasal PYY(3-36) as administered at these intervention doses and preprandial timing is not efficacious in inducing weight loss in obese patients after 12 wk of treatment.